Cadila gets CDSCO panel nod to manufacture, market Calcium Polystyrene Sulphonate suspension
New Delhi: Pharmaceutical major Cadila Healthcare has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) for the manufacturing and marketing of Calcium Polystyrene Sulphonate suspension 15g/60ml indicated for the treatment of hyperkalemia associated with oliguria, anuria, or dialysis.
This came after the firm presented data/justification before the committee for approval of Calcium Polystyrene Sulphonate suspension 15g/60ml in accordance with the earlier SEC recommendation.
Polystyrene sulfonates are polymers derived from polystyrene by the addition of sulfonate functional groups. They are widely used as ion-exchange resins to remove ions such as potassium, calcium, and sodium from solutions in technical or medical applications. Additionally, they can be used to remove toxins.
Increased potassium levels in the blood are treated with calcium polystyrene sulphonate. It's given to those who have renal difficulties or are on dialysis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.